{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-021548","form_type":"8-K","ticker":"RGNX","cik":"0001590877","company_name":"REGENXBIO Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.316554+00:00","generated_at":"2026-06-22T09:03:31.645112+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"REGENXBIO Q3 net loss $75.5M; cash $617M; RGX-314 BLA on track for 2024","bullets":["Net loss of $75.5M ($1.75/share) vs $58.4M ($1.37/share) in Q3 2021; revenue $26.5M, down from $30.8M.","Cash, equivalents & marketable securities $617M as of Sept 30, 2022, down from $849.3M at Dec 31, 2021; runway into 2025.","RGX-314 subretinal pivotal trials (ATMOSPHERE, ASCENT) enrolling; BLA filing planned in 2024. AAVIATE and ALTITUDE trials expanded with new cohorts.","RGX-202 AFFINITY DUCHENNE Phase I/II trial on track for first patient dosing in H1 2023; RGX-121 CAMPSIITE pivotal trial enrolling for MPS II.","Zolgensma royalty revenue $25.2M in Q3 2022 vs $30.3M in Q3 2021; Novartis reported Q3 global sales of $319M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-021548","json":"https://secwatch.observer/filing/0000950170-22-021548.json","markdown":"https://secwatch.observer/filing/0000950170-22-021548.md","text":"https://secwatch.observer/filing/0000950170-22-021548.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590877/000095017022021548/0000950170-22-021548-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590877/000095017022021548/rgnx-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T09:03:31.645112+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"638d26c689c98b64a316856cef4ea19d365acc94","claim":"REGENXBIO Inc. reported financial results for third quarter ended September 30, 2022.","evidence_excerpt":"On November 3, 2022, REGENXBIO Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590877/000095017022021548/0000950170-22-021548-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}